CroíValve is an early stage medical device company focused on developing a minimally invasive device for the treatment of tricuspid regurgitation. It is based in Dublin, Ireland and combines significant clinical, technical and commercial experience.

Lucy O'Keeffe: CEO

Lucy has extensive experience leading medical device development programs. She worked as a cross-functional lead at Medtronic, managing R&D programs from concept to launch, including an early transcatheter aortic program. Additionally, she worked in Nypro Healthcare, managing multiple complex, cross-functional, global projects developing drug delivery devices for top tier pharmaceutical clients and in a CRO, ICON PLC, where she developed an understanding of clinical trials. 

She holds a degree in Mechanical Engineering from University College Dublin, a PhD in Biomedical Engineering from University of Limerick and a Diploma in Project Management from University College Cork.

Dr Martin Quinn: CMO

Martin is a consultant Interventional Cardiologist in St Vincent’s University Hospital and Blackrock Clinic with in-depth knowledge of the disease state and percutaneous methodologies to treat cardiovascular disease. He completed an interventional cardiology fellowship at the Cleveland Clinic, and has led the development of percutaneous valve therapies in Ireland, performing the first TAVI implant in Ireland in 2008. He acts as an expert reviewer for the Irish Health Products Regulatory Authority. He has filed multiple patents for cardiovascular devices and first patented the CroíValve concept in 2014.

He studied medicine at UCD, completed an MSc in Cardiology at Trinity College and was awarded a PhD in Thrombosis for his research on platelet biology and thrombosis at the Royal College of Surgeons in Ireland in 2001.

Dr Ivan Vesely: CTO

Ivan is a structural heart device innovator, expert in heart valve design and tissue biomechanics. He was founder and CTO/CSO of ValveXchange, an early stage company focusing on minimally invasive aortic heart valve surgery. He invented the technology and led the company from concept development, through pre-clinical testing, to clinical implants, completing 45 successful surgical procedures. Previously he was an Endowed Professor of Bioengineering and Cardiothoracic Surgery at the University of Southern California and he established the Heart Valve Laboratory at Cleveland Clinic, building it over 10 years into the most well-funded, highly recognized heart valve research program in the U.S. Before joining CroiValve in late 2018, he has worked as a product expert with BSI Americas - a CE Marking Notified Body.

He has a BS in Electrical Engineering and a Ph.D. in Biophysics from The University of Western Ontario, London, Canada.

Board of Directors

Bernard Collins: Chairman

As the chairman of CroiValve, Dr Bernard Collins brings a wealth of business experience. He serves on the Board of Directors of several U.S. and Irish life-science companies. Prior to forming Lifemed, his consultancy company, Dr Collins served for 10 years as Vice President of International Operations at Boston Scientific Corporation and before this held senior executive positions in life-science companies including Baxter Corporation. His general management experience in the medical device and health care industry spans start-ups, turnarounds, leveraged buyouts and IPOs for both large and small businesses. 

Dr Collins holds a BA Honors in Applied Industrial Psychology/Business from University College Cork, Ireland and an honorary Doctorate in Law from the National University of Ireland Galway. He is a recipient of the prestigious RDS Gold Medal for Industry in recognition of his extraordinary contribution to the development of the biomedical industry in Ireland . 

Robert (Chip) Hance

Robert (Chip) Hance is the former CEO of Creganna Medical, an Ireland-based medical device company with over 2,000 employees worldwide that was acquired by TE Connectivity in 2016. In 2012-13, Chip was an Entrepreneur-in-Residence at the Center for Devices and Radiological Health within the United States Food and Drug Administration (FDA), where he co-led the Innovation Pathway team focused on streamlining aspects of medical device clinical trials in the U.S.

Prior to his FDA experience, Chip was most recently President of Abbott Vascular, the cardiovascular device division of Abbott. Over a decade in interventional cardiology at Abbott Vascular, he led the organization to global leadership in the drug-eluting stent market through the launch of Xience in the U.S., Japan and China. Chip also led the development and CE marking of Absorb, a bioabsorbable scaffold for the treatment of coronary disease and the acquisition and international expansion of Mitraclip, a percutaneous mitral valve repair device.

Chip earned a bachelor’s degree in Chemical Engineering from the Massachusetts Institute of Technology and a master’s degree in Business Administration from Harvard Business School.

Helen Ryan

Helen has over 25 years’ experience in the Medical device industry including as Chief Executive Officer of Creganna Medical and Product Development and Research roles at Medtronic and Covidien. She has demonstrated the ability to scale, including acquiring and integrating companies, establishing strategic joint ventures and raising of debt and equity financing. 

She now works with Irish companies supporting them to scale. She serves as a director for Enterprise Ireland and a number of early stage Medical device companies and charities. She acts as an advisor to Atlantic Bridge Ventures University Bridge Fund and is currently the Chair of the Implementation Group on Police Reform having recently served as a member of the Commission on the Future of Policing in Ireland. 

Helen has a Bachelor of Engineering from NUI Galway, a Masters in Project Management from UL, and has completed a Senior Executive Programme at Stanford University. Helen has received an honorary Doctorate from NUIG and is a fellow of the Institute of Engineers of Ireland and a member of the Irish Academy of Engineers.